EP2197434A4 - Resveratrol-containing compositions for modulating gene product concentration or activity - Google Patents

Resveratrol-containing compositions for modulating gene product concentration or activity

Info

Publication number
EP2197434A4
EP2197434A4 EP08831905A EP08831905A EP2197434A4 EP 2197434 A4 EP2197434 A4 EP 2197434A4 EP 08831905 A EP08831905 A EP 08831905A EP 08831905 A EP08831905 A EP 08831905A EP 2197434 A4 EP2197434 A4 EP 2197434A4
Authority
EP
European Patent Office
Prior art keywords
resveratrol
activity
gene product
containing compositions
product concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08831905A
Other languages
German (de)
French (fr)
Other versions
EP2197434A1 (en
Inventor
William F Sardi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resveratrol Partners LLC
Original Assignee
Resveratrol Partners LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resveratrol Partners LLC filed Critical Resveratrol Partners LLC
Publication of EP2197434A1 publication Critical patent/EP2197434A1/en
Publication of EP2197434A4 publication Critical patent/EP2197434A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP08831905A 2007-09-20 2008-09-17 Resveratrol-containing compositions for modulating gene product concentration or activity Withdrawn EP2197434A4 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US97381707P 2007-09-20 2007-09-20
US2322708P 2008-01-24 2008-01-24
US2323008P 2008-01-24 2008-01-24
US2323408P 2008-01-24 2008-01-24
US4875608P 2008-04-29 2008-04-29
US4876908P 2008-04-29 2008-04-29
US4874708P 2008-04-29 2008-04-29
PCT/US2008/076707 WO2009039195A1 (en) 2007-09-20 2008-09-17 Resveratrol-containing compositions for modulating gene product concentration or activity

Publications (2)

Publication Number Publication Date
EP2197434A1 EP2197434A1 (en) 2010-06-23
EP2197434A4 true EP2197434A4 (en) 2011-08-10

Family

ID=40468316

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08831905A Withdrawn EP2197434A4 (en) 2007-09-20 2008-09-17 Resveratrol-containing compositions for modulating gene product concentration or activity

Country Status (4)

Country Link
EP (1) EP2197434A4 (en)
JP (2) JP2010540444A (en)
CA (1) CA2699908C (en)
WO (1) WO2009039195A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263051B2 (en) * 2007-08-09 2012-09-11 Hallstar Innovations Corp. Photostabilization of resveratrol with alkoxycrylene compounds
JP5979810B2 (en) * 2009-10-09 2016-08-31 株式会社山田養蜂場本社 Anti-aging agent
JP2013518034A (en) * 2010-01-21 2013-05-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Special composition for use as a drug
US20120058088A1 (en) * 2010-06-28 2012-03-08 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Methods Of Use
US8916528B2 (en) 2011-11-16 2014-12-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
JP5608629B2 (en) * 2011-11-28 2014-10-15 アピオン・ジャパン有限会社 Sirtuin 1 (SIRT1) gene activator and telomerase reverse transcriptase (TERT) gene activator
EP2895861A4 (en) * 2012-09-12 2016-06-22 Berg Llc Use of markers in the identification of cardiotoxic agents
CN102908338B (en) * 2012-11-20 2014-05-14 晨光生物科技集团天津有限公司 Preparation method of resveratrol microcapsule
US9138453B2 (en) 2013-10-14 2015-09-22 Biomarker Pharmaceuticals, Inc. Nutrient combinations for affecting an aging process
JP5933633B2 (en) * 2014-06-18 2016-06-15 アピオン・ジャパン有限会社 Sirtuin 1 (SIRT1) gene activator and telomerase reverse transcriptase (TERT) gene activator
WO2016102985A1 (en) * 2014-12-23 2016-06-30 Barokes Pty Ltd. Container for a consumable good, coated with a resveratrol containing layer
US10702571B2 (en) 2015-12-03 2020-07-07 The University Of North Carolina At Pembroke Materials for cathepsin B enhancement and methods of use
JP6272946B2 (en) * 2016-05-20 2018-01-31 株式会社山田養蜂場本社 Anti-aging agent
CA3047429A1 (en) 2017-01-23 2018-07-26 Regeneron Pharmaceuticals, Inc. Hsd17b13 variants and uses thereof
KR20190139869A (en) 2017-04-11 2019-12-18 리제너론 파마슈티칼스 인코포레이티드 Assays for Screening the Activity of Regulators of Members of the Hydroxysteroid (17-Beta) Dehydrogenase (HSD17B) Family
SG11202003254SA (en) 2017-10-11 2020-05-28 Regeneron Pharma Inhibition of hsd17b13 in the treatment of liver disease in patients expressing the pnpla3 i148m variation
JP6411624B2 (en) * 2017-12-26 2018-10-24 株式会社山田養蜂場本社 Anti-aging agent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158376A1 (en) * 2003-10-23 2005-07-21 Sardi William F. Dietary supplement and method of processing same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006298876A (en) * 2005-04-25 2006-11-02 Saisentan Igaku Kenkyusho:Kk Composition containing sirtuin-activating agent and used for treating various eye diseases
CN102125538B (en) * 2003-05-27 2014-05-07 帝斯曼知识产权资产管理有限公司 Novel nutraceutical compositions and use thereof
WO2005002555A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cell/organism lifespan/stress response
WO2005099761A1 (en) * 2004-04-07 2005-10-27 Resveratrol Partners, Llc Dietary supplement and method of processing same
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
EP2388263A1 (en) * 2005-08-04 2011-11-23 Sirtris Pharmaceuticals, Inc. Imidazo[2,1-b]thiazole derivatives as sirtuin modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158376A1 (en) * 2003-10-23 2005-07-21 Sardi William F. Dietary supplement and method of processing same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2009039195A1 *

Also Published As

Publication number Publication date
JP2010540444A (en) 2010-12-24
JP2014058574A (en) 2014-04-03
CA2699908A1 (en) 2009-03-26
WO2009039195A1 (en) 2009-03-26
EP2197434A1 (en) 2010-06-23
CA2699908C (en) 2012-09-11

Similar Documents

Publication Publication Date Title
EP2197434A4 (en) Resveratrol-containing compositions for modulating gene product concentration or activity
HK1245088A1 (en) Modulation of activity of proneurotrophins
GB2460957B (en) Desktop sterilizer for books
SI2334705T1 (en) Biological products
HK1163689A1 (en) Methods and compositions for modulating ire1, src, and abl activity ire1src abl
GB0614780D0 (en) Biological products
GB0612928D0 (en) Biological products
GB0620729D0 (en) Biological products
PL2303891T3 (en) Pyrazolo-quinazolines as protein kinase activity modulators
EP2268825A4 (en) Immobilized product tolerant microorganisms
PL2222311T3 (en) Liquid nucleotides/nucleosides-containing product
PL2271660T3 (en) Stabilized liquid enzyme compositions
GB201106793D0 (en) Droplet-based System
IL192925A0 (en) 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
EP2166093A4 (en) Pharmaceutical composition for enzyme replacement therapy
GB0807413D0 (en) Biological products
GB0720967D0 (en) Anti-material pharmaceutical composition
ZA200908556B (en) Mixed product
EP2015782A4 (en) Compositions and methods for modulating gene expression
EP2196525A4 (en) Jasminum sambac-like fragrance composition
EP2271739A4 (en) Product for cell culture
GB0702681D0 (en) DNA-based biosensors
GB0703971D0 (en) Product carrier
ITMI20071255A1 (en) CONTAINER FOR VERSIBLE PRODUCTS
GB0718833D0 (en) Biological products

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100329

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20110708

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/7056 20060101ALI20110704BHEP

Ipc: A61K 31/05 20060101AFI20110704BHEP

17Q First examination report despatched

Effective date: 20130715

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150401